Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections
- PMID: 17954694
- PMCID: PMC2223921
- DOI: 10.1128/AAC.00813-07
Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections
Abstract
Exposure-response analyses were performed to test the microbiological and clinical efficacies of tigecycline in complicated intra-abdominal infections where Escherichia coli and Bacteroides fragilis are the predominant pathogens. Data from evaluable patients enrolled in three clinical trials were pooled. Patients received intravenous tigecycline (100-mg loading dose followed by 50 mg every 12 h or 50-mg loading dose followed by 25 mg every 12 h). At the test-of-cure visit, microbiological and clinical responses were evaluated. Patients were prospectively classified into cohorts based on infection with a baseline pathogen(s): E. coli only (cohort 1), other mono- or polymicrobial Enterobacteriaceae (cohort 2), at least one Enterobacteriaceae pathogen plus an anaerobe(s) (cohort 3), at least one Enterobacteriaceae pathogen plus a gram-positive pathogen(s) (cohort 4), and all other pathogens (cohort 5). The cohorts were prospectively combined to increase sample size. Logistic regression was used to evaluate ratio of steady-state 24-hour area under the concentration-time curve (AUC) to MIC as a response predictor, and classification-and-regression-tree (CART) analyses were utilized to determine AUC/MIC breakpoints. Analysis began with cohorts 1, 2, and 3 pooled, which included 71 patients, with 106 pathogens. The small sample size precluded evaluation of cohorts 1 (34 patients, 35 E. coli pathogens) and 2 (16 patients, 24 Enterobacteriaceae). CART analyses identified a significant AUC/MIC breakpoint of 6.96 for microbiological and clinical responses (P values of 0.0004 and 0.399, respectively). The continuous AUC/MIC ratio was also borderline predictive of microbiological response (P = 0.0568). Cohort 4 (21 patients, 50 pathogens) was evaluated separately; however, an exposure-response relationship was not detected; cohort 5 (31 patients, 60 pathogens) was not evaluated. The prospective approach of creating homogenous populations of pathogens was critical for identifying exposure-response relationships in complicated intra-abdominal infections.
Figures


References
-
- Babinchak, T., E. Ellis-Grosse, N. Dartois, G. M. Rose, and E. Loh. 2005. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41(Suppl. 5):S354-S367. - PubMed
-
- Bartlett, J. G., A. B. Onderdonk, T. Louie, D. L. Kasper, and S. L. Gorbach. 1978. A review. Lessons from an animal model of intra-abdominal sepsis. Arch. Surg. 113:853-857. - PubMed
-
- Christou, N. V., P. S. Barie, E. P. Dellinger, J. P. Waymack, and H. H. Stone. 1993. Surgical Infection Society intra-abdominal infection study. Prospective evaluation of management techniques and outcome. Arch. Surg. 128:193-198. - PubMed
-
- Dellinger, E. P., M. J. Wertz, J. L. Meakins, J. S. Solomkin, M. D. Allo, R. J. Howard, and R. L. Simmon. 1985. Surgical infection stratification system for intra-abdominal infection. Multicenter trial. Arch. Surg. 120:21-29. - PubMed
-
- Exposure-Response Working Group. April 2003, posting date. Guidance for industry: exposure-response relationships—study design, data analysis, and regulatory applications. U.S. Department of Health and Human Services, Rockville, MD. http://www.fda.gov/cber/gdlns/exposure.htm.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical